Carmat SA is a medtech that designs, manufactures and markets the Aeson artificial heart. It focuses on Aeson to make the first alternative to a heart transplant, and thus provide a therapeutic solution for people suffering from end-stage biventricular heart failure. The company was founded by Pouletty Philippe and Alain Carpentier on June 25, 2008 and is headquartered in Vélizy Villacoublay, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company